Expand HCM Menu
HCM MENU

HCM Latest Press Releases

-- May 21, 2026 --

HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting Globe Newswire 8:00 PM

-- April 29, 2026 --

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing Globe Newswire 8:44 AM
HUTCHMED Announces NDA Acceptance in China with Priority Review Status and Breakthrough Designation for Sovleplenib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia Globe Newswire 6:00 AM

-- April 23, 2026 --

International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on April 28, 2026 Globe Newswire 8:35 AM

-- April 8, 2026 --

HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026 Globe Newswire 8:00 PM

-- March 22, 2026 --

HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China Globe Newswire 8:00 PM

-- March 9, 2026 --

HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK in China Globe Newswire 5:30 AM

-- March 6, 2026 --

Intended Retirement of Independent Non-executive Director and changes of composition of board committees Globe Newswire 3:30 AM

-- March 5, 2026 --

HUTCHMED Reports 2025 Full Year Results and Business Updates Globe Newswire 6:00 AM

-- March 4, 2026 --

HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors Globe Newswire 3:30 AM

-- February 6, 2026 --

HUTCHMED to Announce 2025 Final Results Globe Newswire 3:30 AM

-- January 13, 2026 --

HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet Globe Newswire 11:00 PM

-- January 6, 2026 --

HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China Globe Newswire 7:00 PM

-- January 4, 2026 --

HUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Nave Pancreatic Ductal Adenocarcinoma Globe Newswire 7:00 PM

-- December 30, 2025 --

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Savolitinib for the treatment of Gastric Cancer Patients with MET Amplification Globe Newswire 5:00 AM
Market Data Delayed 15 Minutes